Table 1.
Baseline characteristics of all individuals in NHIS-COVID-19 cohort
Variable | Number (%) | Mean (SD) |
---|---|---|
Age, year | ||
20–29 | 32,380 (26.0) | |
30–39 | 13,154 (10.6) | |
40–49 | 16,519 (13.3) | |
50–59 | 25,260 (20.3) | |
60–69 | 19,669 (15.8) | |
70–79 | 10,426 (8.4) | |
≥ 80 | 6922 (9.2) | |
Sex, male | 48,726 (39.2) | |
Residence | ||
Seoul | 8056 (6.5) | |
Gyeonggi-do | 81,493 (65.5) | |
Daegu | 6855 (5.5) | |
Gyeongsangbuk-do | 15,107 (12.2) | |
Other area | 12,819 (10.3) | |
Underlying disability | 7655 (6.2) | |
Income level | ||
Q1 (Lowest) | 32,387 (26.0) | |
Q2 | 24,979 (20.1) | |
Q3 | 27,774 (22.3) | |
Q4 (Highest) | 37,069 (29.8) | |
Unknown | 2121 (1.7) | |
Charlson comorbidity index | 1.8 (2.9) | |
Hypertension | 32,727 (26.3) | |
DM without chronic complication | 13,781 (11.1) | |
DM with chronic complication | 4255 (3.4) | |
Peripheral vascular disease | 7198 (5.8) | |
Renal disease | 1392 (1.1) | |
Rheumatic disease | 2958 (2.4) | |
Dementia | 3926 (3.2) | |
Peptic ulcer disease | 9872 (7.9) | |
Hemiplegia or paraplegia | 568 (0.5) | |
Moderate or severe liver disease | 146 (0.1) | |
Mild liver disease | 13,612 (10.9) | |
Cerebrovascular disease | 5763 (4.6) | |
Congestive heart failure | 3683 (3.0) | |
Myocardial infarction | 1187 (1.0) | |
Malignancy | 22,013 (17.7) | |
Metastatic solid tumor | 4072 (3.3) | |
AIDS/HIV | 32 (0.0) | |
Any chronic respiratory diseases | 36,365 (29.2) | |
COPD | 4488 (3.6) | |
Asthma | 33,858 (27.2) | |
Interstitial lung disease | 421 (0.3) | |
Lung cancer | 769 (0.6) | |
Lung disease d/t external agent | 437 (0.4) | |
Obstructive sleep apnea | 550 (0.4) | |
Tuberculosis of lung | 608 (0.5) |
SD, standard deviation; DM, diabetes mellitus; AIDS, acquired immune deficiency syndrome; HIV, Human Immunodeficiency Virus